BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Basic Materials, Industrials and Technology sectors led shares higher. At the close in NYSE, the...
Gainers: TIS +37%. HMNY +37%. CRON +21%. TLRY +20%. ALNY +17%. JMEI +17%. CTXR +18%. LAC +15%. KONE +14%. LEVB +13%. Losers: EIDX -31%. ECR -13%. PTX -11%. GURE -11%. FOSL -9%....
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced a collaboration agreement with Stealth BioTherapeutics Corp (NASDAQ:MITO) for a late-stage therapy for mitochondrial...
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were down 4.5% after it announced the departure of its current chief financial officer, Paul Clancy, later this year.Shares...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced a license agreement with BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (NASDAQ:EIDX)...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||5H||3||Nov 13, 2019 08:00AM|
|Doji Star Bearish||30||4||Nov 14, 2019 01:30PM|
|Doji Star Bearish||1M||5||Jun 19|
|Doji Star Bearish||15||6||Nov 14, 2019 01:30PM|
|Advance Block Bearish||1M||7||Apr 19|
|Bank of America||32.70||32.86||32.49||-0.09||-0.27%||35.58M||14/11|
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.